As previously reported, BofA downgraded Procept BioRobotics (PRCT) to Neutral from Buy with a price target of $38, down from $55. Procept still has a large potential market opportunity with its aquablation technology to treat benign prostatic hyperplasia, but utilization growth has slowed and changes in the works aimed at improving utilization could cause some near-term disruption, the analyst tells investors. Utilization growth and systems both slowing “doesn’t instill confidence in upside,” the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- Procept BioRobotics downgraded to Neutral from Buy at BofA
- Procept BioRobotics price target lowered to $51 from $56 at Morgan Stanley
- Procept Biorobotics Earnings Call: Growth Amid Challenges
- Procept BioRobotics price target lowered to $50 from $55 at Piper Sandler
- Procept BioRobotics price target lowered to $50 from $85 at TD Cowen